$ACHC
Acadia Healthcare Company, Inc.

2017 Q1 Form 10-Q Financial Statement

#000119312517139502 Filed on April 26, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $689.3M $616.8M
YoY Change 11.76% 68.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $466.5M $422.5M
YoY Change 10.41% 68.73%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $33.60M $28.00M
YoY Change 20.0% 113.74%
% of Gross Profit
Operating Expenses $630.7M $584.3M
YoY Change 7.94% 69.58%
Operating Profit $136.4M $131.0M
YoY Change 4.09% 66.44%
Interest Expense -$42.80M -$37.30M
YoY Change 14.75% 68.78%
% of Operating Profit -31.39% -28.47%
Other Income/Expense, Net
YoY Change
Pretax Income $48.48M $32.48M
YoY Change 49.28% 53.17%
Income Tax $13.71M $7.110M
% Of Pretax Income 28.28% 21.89%
Net Earnings $34.96M $25.69M
YoY Change 36.09% 76.02%
Net Earnings / Revenue 5.07% 4.16%
Basic Earnings Per Share $0.40 $0.31
Diluted Earnings Per Share $0.40 $0.31
COMMON SHARES
Basic Shares Outstanding 86.76M shares 82.94M shares
Diluted Shares Outstanding 86.91M shares 83.42M shares

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.10M $36.60M
YoY Change 17.76% -3.68%
Cash & Equivalents $43.09M $36.58M
Short-Term Investments
Other Short-Term Assets $104.8M $79.80M
YoY Change 31.37% 2.84%
Inventory $4.723M $4.779M
Prepaid Expenses $28.42M $29.40M
Receivables $276.1M $276.9M
Other Receivables $45.77M $22.88M
Total Short-Term Assets $424.0M $393.3M
YoY Change 7.82% 20.86%
LONG-TERM ASSETS
Property, Plant & Equipment $2.750B $3.338B
YoY Change -17.62% 171.43%
Goodwill $2.684B $2.771B
YoY Change -3.16% 45.55%
Intangibles $83.72M $102.6M
YoY Change -18.4% 75.35%
Long-Term Investments
YoY Change
Other Assets $61.73M $49.62M
YoY Change 24.4% -28.12%
Total Long-Term Assets $5.642B $6.303B
YoY Change -10.49% 90.9%
TOTAL ASSETS
Total Short-Term Assets $424.0M $393.3M
Total Long-Term Assets $5.642B $6.303B
Total Assets $6.066B $6.696B
YoY Change -9.42% 84.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $92.67M $118.2M
YoY Change -21.6% 82.09%
Accrued Expenses $41.89M $140.2M
YoY Change -70.12% 7.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $34.81M $69.22M
YoY Change -49.72% 96.05%
Total Short-Term Liabilities $335.9M $408.8M
YoY Change -17.85% 77.23%
LONG-TERM LIABILITIES
Long-Term Debt $3.247B $3.498B
YoY Change -7.18% 73.26%
Other Long-Term Liabilities $166.0M $124.5M
YoY Change 33.34% 52.97%
Total Long-Term Liabilities $3.413B $3.622B
YoY Change -5.78% 72.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $335.9M $408.8M
Total Long-Term Liabilities $3.413B $3.622B
Total Liabilities $3.812B $4.126B
YoY Change -7.6% 73.54%
SHAREHOLDERS EQUITY
Retained Earnings $263.7M $239.7M
YoY Change 10.02% 106.56%
Common Stock $2.501B $2.476B
YoY Change 0.98% 101.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.236B $2.563B
YoY Change
Total Liabilities & Shareholders Equity $6.066B $6.696B
YoY Change -9.42% 84.62%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income $34.96M $25.69M
YoY Change 36.09% 76.02%
Depreciation, Depletion And Amortization $33.60M $28.00M
YoY Change 20.0% 113.74%
Cash From Operating Activities $57.01M $58.66M
YoY Change -2.81% 221.94%
INVESTING ACTIVITIES
Capital Expenditures $50.55M $90.09M
YoY Change -43.89% 70.37%
Acquisitions $580.1M
YoY Change 1069.12%
Other Investing Activities $5.051M $1.208M
YoY Change 318.13% 215.4%
Cash From Investing Activities -$58.10M -$685.4M
YoY Change -91.52% 555.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $685.0M
YoY Change -100.0% 80.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.70M 654.0M
YoY Change -102.09% 1905.89%
NET CHANGE
Cash From Operating Activities 57.01M 58.66M
Cash From Investing Activities -58.10M -685.4M
Cash From Financing Activities -13.70M 654.0M
Net Change In Cash 57.01M 58.66M
YoY Change -2.81% -209.09%
FREE CASH FLOW
Cash From Operating Activities $57.01M $58.66M
Capital Expenditures $50.55M $90.09M
Free Cash Flow $6.465M -$31.43M
YoY Change -120.57% -9.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 achc Consolidated Funded Debt Maximum
ConsolidatedFundedDebtMaximum
40000000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87817913 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36582000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
102333000
CY2017Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3247000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
248084000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86916624 shares
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7677000
CY2017Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
45766000
CY2017Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3247000
CY2017Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
34805000
CY2017Q1 us-gaap Insurance Receivable For Malpractice Current
InsuranceReceivableForMalpracticeCurrent
6472000
CY2017Q1 us-gaap Liabilities
Liabilities
3812287000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86916624 shares
CY2017Q1 us-gaap Assets
Assets
6065790000
CY2017Q1 us-gaap Foreign Currency Contract Asset Fair Value Disclosure
ForeignCurrencyContractAssetFairValueDisclosure
59300000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
424013000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2499760000
CY2017Q1 us-gaap Derivative Instruments And Hedges Noncurrent
DerivativeInstrumentsAndHedgesNoncurrent
59257000
CY2017Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
41121000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43087000
CY2017Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
3750000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
276089000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
869000
CY2017Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
11672000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
92673000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22260000
CY2017Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2658000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-528392000
CY2017Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
63858000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41887000
CY2017Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
83718000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3246577000
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
3281382000
CY2017Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
2271000
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
104837000
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
83718000
CY2017Q1 us-gaap Inventory Net
InventoryNet
4723000
CY2017Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
39 State
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6065790000
CY2017Q1 us-gaap Goodwill
Goodwill
2683787000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
165995000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
335857000
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28423000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106046000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4402000
CY2017Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
7182000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61727000
CY2017Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
86965000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2749538000
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2997622000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
46.59
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
2235933000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.08
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
466320 shares
CY2017Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
7542000
CY2017Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
17570000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
263696000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4281213 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8200000 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4298000
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
12350000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1134108 shares
CY2017Q1 achc Workers Compensation Deposits
WorkersCompensationDeposits
10000000
CY2017Q1 achc Number Of Beds
NumberOfBeds
17200 Beds
CY2017Q1 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
0
CY2017Q1 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
3247000
CY2017Q1 achc Debt Instrument Unamortized Issuance Costs Discount Premium Net
DebtInstrumentUnamortizedIssuanceCostsDiscountPremiumNet
57606000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11215000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20717000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.87
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
694743 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
61.00
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11500000 shares
CY2016Q1 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
15800000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
105068000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3247000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
214589000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86688199 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86688199 shares
CY2016Q4 us-gaap Assets
Assets
6024726000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
427927000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2496288000
CY2016Q4 us-gaap Derivative Instruments And Hedges Noncurrent
DerivativeInstrumentsAndHedgesNoncurrent
73509000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
38916000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57063000
CY2016Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
3780000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
263327000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
867000
CY2016Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
11672000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
80034000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28805000
CY2016Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2732000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-549570000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
78520000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37323000
CY2016Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
83310000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3253004000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
3287809000
CY2016Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
2288000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3247000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
34805000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
107537000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
83310000
CY2016Q4 us-gaap Inventory Net
InventoryNet
4633000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8283000
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
44975000
CY2016Q4 us-gaap Insurance Receivable For Malpractice Current
InsuranceReceivableForMalpracticeCurrent
6472000
CY2016Q4 us-gaap Liabilities
Liabilities
3839248000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6024726000
CY2016Q4 us-gaap Goodwill
Goodwill
2681188000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
164859000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
342865000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
27455000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122958000
CY2016Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
11714000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51317000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8166000
CY2016Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
86557000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2703695000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2918284000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.81
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2167724000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.42
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
288959 shares
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
527000
CY2016Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
17754000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
220139000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6111000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
33616000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000946 shares
CY2016Q4 achc Workers Compensation Deposits
WorkersCompensationDeposits
10000000
CY2016Q4 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
0
CY2016Q4 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
3247000
CY2016Q4 achc Debt Instrument Unamortized Issuance Costs Discount Premium Net
DebtInstrumentUnamortizedIssuanceCostsDiscountPremiumNet
59816000
CY2016Q4 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-02-13
CY2016Q4 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
320000000
CY2016Q4 achc Number Of Beds To Be Sold
NumberOfBedsToBeSold
1000 Bed
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
685000000
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
52000000
us-gaap Reinsurance Retention Policy Amount Retained
ReinsuranceRetentionPolicyAmountRetained
2000000
us-gaap Reinsurance Retention Policy Excess Retention Amount Reinsured
ReinsuranceRetentionPolicyExcessRetentionAmountReinsured
50000000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
57397 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
57.98
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M19D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
140250 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
31.92
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.35 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1530000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
503850 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.96
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014 pure
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
57.13
CY2016 achc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y3M11D
CY2016 achc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
297000
CY2016 achc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue
0
CY2017Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2396000
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Acadia Healthcare Company, Inc.
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1200000 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001520697
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7396000
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13976000
CY2017Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-425000
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
842000
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2017Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4119000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33613000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
56136000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2017Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-185000
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.283 pure
CY2017Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2007000
CY2017Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
18971000
CY2017Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
5051000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-5868000
CY2017Q1 us-gaap Other Comprehensive Income Derivatives Qualifying As Hedges Tax Portion Attributable To Parent
OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxPortionAttributableToParent
-5600000
CY2017Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
376421000
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5886000
CY2017Q1 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
8599000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
630710000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
34958000
CY2017Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-185000
CY2017Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
83711000
CY2017Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
679194000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
48484000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-58095000
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
27046000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13711000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
57439000
CY2017Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
CY2017Q1 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
10147000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12459000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
57014000
CY2017Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
CY2017Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2142000
CY2017Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
CY2017Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
CY2017Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
2495000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
21178000
CY2017Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
8782000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1710000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
136369000
CY2017Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-42757000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-13737000
CY2017Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
689341000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16993000
CY2017Q1 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
27709000
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3437000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3825000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50549000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11350 shares
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
312000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
55951000
CY2017Q1 us-gaap Severance Costs1
SeveranceCosts1
1664000
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86908000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y4M24D
CY2017Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
8638000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
20.50
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86762000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
42.77
CY2017Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
146000 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M7D
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
52888 shares
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2017Q1 dei Trading Symbol
TradingSymbol
ACHC
CY2017Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
65200000
CY2017Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.33 pure
CY2017Q1 us-gaap Professional Fees
ProfessionalFees
43409000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
228000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
197400 shares
CY2017Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-865000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
34773000
CY2017Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.57
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020 pure
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7396000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
54.87
CY2017Q1 achc Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
CY2017Q1 achc Number Of Facilities
NumberOfFacilities
575 Facilities
CY2017Q1 achc Common Stock Withheld For Minimum Statutory Taxes Net
CommonStockWithheldForMinimumStatutoryTaxesNet
4234000
CY2017Q1 achc Share Based Compensation Arrangement By Share Based Payment Stock Options Granted Term
ShareBasedCompensationArrangementByShareBasedPaymentStockOptionsGrantedTerm
P10Y
CY2017Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue
0
CY2017Q1 achc Common Stock Withheld For Minimum Statutory Taxes
CommonStockWithheldForMinimumStatutoryTaxes
4439000
CY2017Q1 achc New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption On Income Tax Provision
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionOnIncomeTaxProvision
1700000
CY2017Q1 achc New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption On Income Tax Provision As Percentage
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionOnIncomeTaxProvisionAsPercentage
0.036 pure
CY2016Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2147000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25367000
CY2016Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-619000
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1819000
CY2017Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y11M16D
CY2017Q1 achc Share Based Compensation Arrangement By Share Based Payment Award
ShareBasedCompensationArrangementByShareBasedPaymentAward
0.25 pure
CY2017Q1 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
2455000
CY2017Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
78000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2016Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
26298000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27975000
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22727000
CY2016Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
2372358000
CY2016Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-319000
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.219 pure
CY2016Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
9085000
CY2016Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
410000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
14806000
CY2016Q1 us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
-745000
CY2016Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1208000
CY2016Q1 us-gaap Other Comprehensive Income Derivatives Qualifying As Hedges Tax Portion Attributable To Parent
OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxPortionAttributableToParent
0
CY2016Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
341028000
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
8075000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
584334000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
25688000
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-319000
CY2016Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
70247000
CY2016Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
616813000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32479000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-685447000
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-48415000
CY2016Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
34167000
CY2016Q1 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
10370000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3749000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58664000
CY2016Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
58000000
CY2016Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
354000
CY2016Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1575380000
CY2016Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
580096000
CY2016Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
14799000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-48415000
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2402000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
131012000
CY2016Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-37714000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
653969000
CY2016Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
627183000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7498000
CY2016Q1 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
26685000
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-6347000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7110000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
59283000
CY2016Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-882000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90089000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
216882000
CY2016Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1348389000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-23046000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83420000 shares
CY2016Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
13669000
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
477000 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82943000 shares
CY2016Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1480000000
CY2016Q1 us-gaap Professional Fees
ProfessionalFees
39991000
CY2016Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-224000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
25369000
CY2016Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
166000000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6956000
CY2016Q1 achc Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
685097000
CY2016Q1 achc Common Stock Withheld For Minimum Statutory Taxes Net
CommonStockWithheldForMinimumStatutoryTaxesNet
6679000
CY2016Q1 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
11448000
CY2016Q1 achc Advisory And Financing Commitment Fees
AdvisoryAndFinancingCommitmentFees
14850000

Files In Submission

Name View Source Status
0001193125-17-139502-index-headers.html Edgar Link pending
0001193125-17-139502-index.html Edgar Link pending
0001193125-17-139502.txt Edgar Link pending
0001193125-17-139502-xbrl.zip Edgar Link pending
achc-20170331.xml Edgar Link completed
achc-20170331.xsd Edgar Link pending
achc-20170331_cal.xml Edgar Link unprocessable
achc-20170331_def.xml Edgar Link unprocessable
achc-20170331_lab.xml Edgar Link unprocessable
achc-20170331_pre.xml Edgar Link unprocessable
d366318d10q.htm Edgar Link pending
d366318dex311.htm Edgar Link pending
d366318dex312.htm Edgar Link pending
d366318dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending